LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:LEXX • US52886N4060

0.725 USD
+0.06 (+9.52%)
At close: Feb 6, 2026
0.7 USD
-0.03 (-3.45%)
After Hours: 2/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

LEXX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While LEXX seems to be doing ok healthwise, there are quite some concerns on its profitability. LEXX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LEXX has reported negative net income.
  • In the past year LEXX has reported a negative cash flow from operations.
  • LEXX had negative earnings in each of the past 5 years.
  • In the past 5 years LEXX always reported negative operating cash flow.
LEXX Yearly Net Income VS EBIT VS OCF VS FCFLEXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -178.37%, LEXX is doing worse than 88.48% of the companies in the same industry.
  • With a Return On Equity value of -219.69%, LEXX is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -178.37%
ROE -219.69%
ROIC N/A
ROA(3y)-188.88%
ROA(5y)-137.97%
ROE(3y)-229.76%
ROE(5y)-162.22%
ROIC(3y)N/A
ROIC(5y)N/A
LEXX Yearly ROA, ROE, ROICLEXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • The Gross Margin of LEXX (100.00%) is better than 97.91% of its industry peers.
  • LEXX's Gross Margin has improved in the last couple of years.
  • LEXX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.9%
GM growth 5Y7.02%
LEXX Yearly Profit, Operating, Gross MarginsLEXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LEXX has been increased compared to 1 year ago.
  • Compared to 5 years ago, LEXX has more shares outstanding
  • LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LEXX Yearly Shares OutstandingLEXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
LEXX Yearly Total Debt VS Total AssetsLEXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • LEXX has an Altman-Z score of -11.56. This is a bad value and indicates that LEXX is not financially healthy and even has some risk of bankruptcy.
  • LEXX has a Altman-Z score of -11.56. This is in the lower half of the industry: LEXX underperforms 74.87% of its industry peers.
  • LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.56
ROIC/WACCN/A
WACC8.59%
LEXX Yearly LT Debt VS Equity VS FCFLEXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 3.68 indicates that LEXX has no problem at all paying its short term obligations.
  • LEXX's Current ratio of 3.68 is in line compared to the rest of the industry. LEXX outperforms 56.54% of its industry peers.
  • A Quick Ratio of 3.68 indicates that LEXX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.68, LEXX perfoms like the industry average, outperforming 58.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68
LEXX Yearly Current Assets VS Current LiabilitesLEXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for LEXX have decreased strongly by -14.29% in the last year.
  • Looking at the last year, LEXX shows a small growth in Revenue. The Revenue has grown by 5.05% in the last year.
  • The Revenue has been growing by 17.89% on average over the past years. This is quite good.
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)5.05%
Revenue growth 3Y39.51%
Revenue growth 5Y17.89%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, LEXX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.83% on average per year.
  • Based on estimates for the next years, LEXX will show a very strong growth in Revenue. The Revenue will grow by 189.59% on average per year.
EPS Next Y37.23%
EPS Next 2Y21.74%
EPS Next 3Y29.83%
EPS Next 5YN/A
Revenue Next Year17.26%
Revenue Next 2Y44.81%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.6%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LEXX Yearly Revenue VS EstimatesLEXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 50M 100M 150M 200M
LEXX Yearly EPS VS EstimatesLEXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LEXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEXX Price Earnings VS Forward Price EarningsLEXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEXX Per share dataLEXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LEXX's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.74%
EPS Next 3Y29.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LEXX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (2/6/2026, 8:00:02 PM)

After market: 0.7 -0.03 (-3.45%)

0.725

+0.06 (+9.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-13
Earnings (Next)04-13
Inst Owners6.9%
Inst Owner Change22.86%
Ins Owners6.01%
Ins Owner Change0%
Market Cap16.12M
Revenue(TTM)522.00K
Net Income(TTM)-10.79M
Analysts82.86
Price Target4.59 (533.1%)
Short Float %5.08%
Short Ratio1.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.93%
Min EPS beat(2)18.65%
Max EPS beat(2)47.21%
EPS beat(4)3
Avg EPS beat(4)9.89%
Min EPS beat(4)-31.41%
Max EPS beat(4)47.21%
EPS beat(8)4
Avg EPS beat(8)0.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-37.74%
Min Revenue beat(2)-100%
Max Revenue beat(2)24.52%
Revenue beat(4)3
Avg Revenue beat(4)8.95%
Min Revenue beat(4)-100%
Max Revenue beat(4)86.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.62%
PT rev (3m)-15.62%
EPS NQ rev (1m)14.29%
EPS NQ rev (3m)20%
EPS NY rev (1m)23.08%
EPS NY rev (3m)23.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.87
P/FCF N/A
P/OCF N/A
P/B 3.28
P/tB 3.5
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.02
BVpS0.22
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -178.37%
ROE -219.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-188.88%
ROA(5y)-137.97%
ROE(3y)-229.76%
ROE(5y)-162.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.9%
GM growth 5Y7.02%
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 294.13%
Cap/Sales 40.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z -11.56
F-Score4
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)212.54%
Cap/Depr(5y)178.07%
Cap/Sales(3y)49.65%
Cap/Sales(5y)45.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y37.23%
EPS Next 2Y21.74%
EPS Next 3Y29.83%
EPS Next 5YN/A
Revenue 1Y (TTM)5.05%
Revenue growth 3Y39.51%
Revenue growth 5Y17.89%
Sales Q2Q%-100%
Revenue Next Year17.26%
Revenue Next 2Y44.81%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.6%
EBIT growth 1Y-47.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.33%
OCF growth 3YN/A
OCF growth 5YN/A

LEXARIA BIOSCIENCE CORP / LEXX FAQ

Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?

ChartMill assigns a fundamental rating of 3 / 10 to LEXX.


What is the valuation status for LEXX stock?

ChartMill assigns a valuation rating of 1 / 10 to LEXARIA BIOSCIENCE CORP (LEXX). This can be considered as Overvalued.


What is the profitability of LEXX stock?

LEXARIA BIOSCIENCE CORP (LEXX) has a profitability rating of 1 / 10.


What is the financial health of LEXARIA BIOSCIENCE CORP (LEXX) stock?

The financial health rating of LEXARIA BIOSCIENCE CORP (LEXX) is 6 / 10.